Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Bryon D. Johnson PhD

Bryon D. Johnson PhD

Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology

Member of the Cancer Center


Publications

  • Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. (Kearl TJ, Jing W, Gershan JA, Johnson BD) J Immunol 2013 Jun 1;190(11):5620-8 PMID 23616570
  • Endothelial and Accessory Cell Interactions in Neuroblastoma Tumor Microenvironment (Chapter Title) (Jill Gershan, Andrew Chan, Magdalena Chrzanowska-Wodnicka, Bryon Johnson, Qing Robert Miao and Ramani Ramchandran) Research Directions in Tumor Angiogenesis (Book Title) ISBN: 978-953-51-0963-1
  • Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. (Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S) J Cancer Res Clin Oncol 2013 May;139(5):727-37 PMID 23354841
  • Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. (Barr KM, Jing W, Hallett WH, Gershan JA, Johnson BD) J Immunother 2013 Jan;36(1):41-51 PMID 23211619
  • HMGB1 Release by Urothelial Carcinoma Cells is Required for the In Vivo Anti-Tumor Response to BCG (Zhang G, Chen F, Cao Y, Johnson B, See WA) The Journal of Urology
  • Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo. (Yan X, Doffek K, Yin C, Krein M, Phillips M, Sugg SL, Johnson B, Shilyansky J) Cancer Immunol Immunother 2012 Nov;61(11):1917-27 PMID 22476407
  • Exciting new murine model of cGVHD. (Johnson BD) Blood 2012 Feb 9;119(6):1331-2 PMID 22323409
  • Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. (Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA) Cancer Microenviron 2013 Apr;6(1):79-89 PMID 22237886
  • Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45 PMID 21536144
  • Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. (Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD) Blood 2011 Jun 23;117(25):6952-62 PMID 21521781
  • Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. (Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S) Anticancer Res 2010 Sep;30(9):3313-9 PMID 20944103
  • Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. (Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ) Cancer Sci 2010 Nov;101(11):2316-24 PMID 20718755
  • Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. (Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ) Cell Immunol 2010;265(1):65-73 PMID 20692654
  • Robert Truitt tribute. (Johnson B, Drobyski W, Blazar B, Korngold R) Biol Blood Marrow Transplant 2010 Jan;16(1):143-4 PMID 19836456
  • Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. (Jing W, Gershan JA, Johnson BD) Blood 2009 Apr 30;113(18):4449-57 PMID 19182203
  • Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. (Yan X, Johnson BD, Orentas RJ) J Immunol 2008 Oct 1;181(7):4621-31 PMID 18802064
  • Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. (Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD) J Immunol 2008 Aug 1;181(3):1877-86 PMID 18641325
  • Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. (Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR) Blood 2007 Nov 15;110(10):3804-13 PMID 17693581
  • Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. (Zhou Q, Johnson BD, Orentas RJ) Cell Immunol 2007 Feb;245(2):91-102 PMID 17543914
  • CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. (Johnson BD, Jing W, Orentas RJ) J Immunother 2007 Feb-Mar;30(2):203-14 PMID 17471167
  • Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. (Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A) Cytotherapy 2007;9(2):144-57 PMID 17453966
  • Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. (Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ) BMC Immunol 2007;8:4 PMID 17397536
  • Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. (Jing W, Orentas RJ, Johnson BD) Biol Blood Marrow Transplant 2007 Mar;13(3):277-92 PMID 17317581
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID 17269937
  • Immune response modulation by curcumin in a latex allergy model. (Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN) Clin Mol Allergy 2007;5:1 PMID 17254346
  • Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. (Xia G, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2006 Apr;12(4):397-407 PMID 16545723
  • Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. (Yan X, Orentas RJ, Johnson BD) Cytokine 2006 Feb 21;33(4):188-98 PMID 16522371
  • Suppression of anti-cancer immunity by regulatory T cells: back to the future. (Orentas RJ, Kohler ME, Johnson BD) Semin Cancer Biol 2006 Apr;16(2):137-49 PMID 16376101
  • The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice. (Barrios CS, Johnson BD, D Henderson J Jr, Fink JN, Kelly KJ, Kurup VP) Clin Exp Immunol 2005 Nov;142(2):242-50 PMID 16232210
  • Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. (Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ) J Immunother 2005 Sep-Oct;28(5):449-60 PMID 16113601
  • Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. (Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA) Blood 2005 Oct 15;106(8):2671-9 PMID 15972454
  • Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. (Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ) Genet Vaccines Ther 2005 Jun 21;3(1):4 PMID 15969754
  • Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. (Xia G, Kovochich M, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2004 Nov;10(11):748-60 PMID 15505606
  • The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. (Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL, Johnson BD) Cell Immunol 2004 Feb;227(2):129-39 PMID 15135295
  • Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. (Yan X, Johnson BD, Orentas RJ) Immunology 2004 May;112(1):105-16 PMID 15096190
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID 14675082
  • CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. (Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL) Blood 2004 Apr 1;103(7):2691-8 PMID 14644999
  • Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. (Johnson BD, Yan X, Schauer DW, Orentas RJ) Cell Immunol 2003 Mar;222(1):15-26 PMID 12798304
  • Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. (Johnson BD, Taylor PA, Stankowski MC, Talib S, Hearst JE, Blazar BR) Biol Blood Marrow Transplant 2002;8(11):581-7 PMID 12463476
  • CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. (Johnson BD, Konkol MC, Truitt RL) Biol Blood Marrow Transplant 2002;8(10):525-35 PMID 12434947
  • Production of macrophage migration inhibitory factor by human and murine neuroblastoma. (Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ) Tumour Biol 2002 May-Jun;23(3):123-9 PMID 12218292
  • Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. (Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL) Biol Blood Marrow Transplant 2001;7(11):589-95 PMID 11760146
  • Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. (Orentas RJ, Schauer D, Bin Q, Johnson BD) Cell Immunol 2001 Oct 10;213(1):4-13 PMID 11747351
  • T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. (Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP) Clin Immunol 2001 Aug;100(2):228-35 PMID 11465952
  • Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). (Banerjee B, Kurup VP, Greenberger PA, Johnson BD, Fink JN) Clin Exp Allergy 2001 May;31(5):761-70 PMID 11422136
  • Purified and recombinant latex proteins stimulate peripheral blood lymphocytes of latex allergic patients. (Johnson BD, Kurup VP, Sussman GL, Arif SA, Kelly KJ, Beezhold DH, Fink JN) Int Arch Allergy Immunol 1999 Dec;120(4):270-9 PMID 10640910
  • Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. (Johnson BD, Becker EE, LaBelle JL, Truitt RL) J Immunol 1999 Dec 15;163(12):6479-87 PMID 10586039
  • Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. (Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE) J Immunol 1999 Nov 1;163(9):5145-56 PMID 10528221
  • Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32 PMID 10392958
  • Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. (Johnson BD, Hanke CA, Becker EE, Truitt RL) Cell Immunol 1998 Nov 1;189(2):149-59 PMID 9790729
  • The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. (Johnson BD, Hanke CA, Truitt RL) Leuk Lymphoma 1996 Sep;23(1-2):1-9 PMID 9021679
  • Principles of graft-vs.-leukemia reactivity. (Truitt RL, Johnson BD) Biol Blood Marrow Transplant 1995 Dec;1(2):61-8 PMID 9118293
  • Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. (Johnson BD, Truitt RL) Blood 1995 Jun 1;85(11):3302-12 PMID 7756664
  • Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. (Johnson BD, McCabe C, Hanke CA, Truitt RL) J Immunol 1995 May 15;154(10):5542-54 PMID 7730653
  • Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). (Wierda WG, Johnson BD, Dato ME, Kim YB) J Immunol 1993 Dec 15;151(12):7117-27 PMID 8258715
  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36 PMID 8485480
  • Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. (Wierda WG, Johnson BD, Dato ME, Kim YB) Cell Immunol 1993 Feb;146(2):270-83 PMID 8174170
  • A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. (Johnson BD, Truitt RL) Transplantation 1992 Jul;54(1):104-12 PMID 1631918
  • Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. (Johnson BD, Wierda WG, Kim YB) Cell Immunol 1991 May;134(2):378-89 PMID 2021974
  • Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). (Johnson BD, Kim YB) Cell Immunol 1990 Jan;125(1):107-19 PMID 2293895
  • C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. (Baum LL, Johnson B, Berman S, Graham D, Mold C) Immunology 1987 May;61(1):93-9 PMID 3583316
  • Grants and Awards

  • Transient Lymphodepletion and PD-1/PD-L1 Blockade to Treat Myeloma (#9207783 12/01/2012 - 11/30/2014) Sponsor: Multiple Myeloma Research Foundation
  • Optimizing Immunotherapy for Neuroblastoma After BMT (#9205544 07/02/2009 - 05/31/2015) Sponsor: NIH Cancer Institute
  • Optimizing Immunotherapy for Neuroblastoma After BMT (#9203311 06/15/2004 - 07/01/2009) Sponsor: NIH Cancer Institute